PPT-AIM 2030 Access to Innovative Medicines

Draft concept for a new World Bankled multistakeholder initiative August 2014 Andreas Seiter What is AIM 2030 An initiative to maximize access to innovative medicines for priority diseases in low and middle income countries LMICs. Access to Innovative Medicines. Draft concept for a new World Bank-led multi-stakeholder initiative . August 2014, Andreas . Seiter. What is AIM 2030?. An initiative to maximize access to innovative medicines for priority diseases in low- and middle income countries (LMICs). Executive Strategy. Introduction to . AMS Council. Mission Statement. “To . improve the quality of the educational, . social. , and personal lives of the students of UBC. .”. History. Spencer Keys (AMS President 2005-2006) developed first “Strategic Framework” for the AMS. –. lessons from HIV. EPIP, 5 September 2017, Bordeaux. . Ellen ‘t Hoen, LLM. University Medical Centre Groningen, Global Health Unit. @. ellenthoen. www.medicineslawandpolicy.org. Brief history. Stops AIDS National Gathering . 1st November 2014. Aliénor Devali. ère. Health. Action International (HAI) Europe. This document arises from HAI Europe’s Operating Grant 2014, which has received funding from the . Gilles Forte. Policy. , Access and Use Team. Department for Essential . Medicines and Health Products. World Health Assembly Resolution 67.22 . Access . to essential medicines. Recognize . the importance of effective national medicines policies, and their . Gilles . Forte. Coordinator, Policy, Access and Use Team. Essential . Medicines . and . Health Products. . WHO . mandate . within the . International . Drug Control Conventions. 1961 . Single Convention on Narcotic Drugs (Article 3). WHO EMP and NVI Departments. Access to NCD essential medicines . on the global agenda. Access to chronic disease medicines is required for the fulfilment of MDG8. Governments, in collaboration with the private sector, should give greater priority to treating chronic diseases and improving the accessibility of medicines to treat them (MDG Report 2009). sustainably and equitably financed. Summary Discussion…1. What information needed to estimate cost program of medicines benefits. MBM . Ned to estimate the total economic cost of setting up a MBM program. Development. Esteban Burrone. Head of Policy. Medicines. Patent Pool. Collaboration to promote innovation and . aCCESS. TO MEDICINES. Innovation. and . Access. are two sides of the same coin and central to ensuring improvements in public health outcomes worldwide. Tuesday 8. th. November 2016, Jubilee Room,. . House of Commons. . Regulating and paying for regenerative medicine products in the NHS – . challenges and opportunities. Flexibilities in regulation that are part of attempts to accelerate access to market of new products. Dr Cécile . Macé. . WHO EMP , Mr Arne-Petter . Sanne. WHO MND, . Mr . Ajuebor. Onyema WHO MND. NCD Programme Managers Seminar. 4 June 2014. Access to NCD essential medicines . on the global agenda. Case Management. George Jagoe . EVP, Access & Product Management, MMV. . . The access team at MMV is heavily focused on the needs of control today. 4. Achieving patient impact means addressing many hurdles to access. Basic enquiry answering. September . 2016. Session aims. Increase awareness of the Medicines Information (MI) services. UK. Wales. Increase awareness of the questions to ask an enquirer. Have practical experience using some resources which will be... Dr. Richard Torbett. Chief Economist, EFPIA. China/ EU Pharmaceutical Industry Forum. Shanghai, . 16 May 2015. Policy debate on health in recent years has been dominated by cost containment. Health & Growth.